tetano
Editor, Senior Moderator
Clin Vaccine Immunol. 2015 Jan 14. pii: CVI.00662-14. [Epub ahead of print]
[h=1]The long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 vaccine with or without aluminium-adjuvantin mice.[/h] Xu W[SUP]1[/SUP], Zheng M[SUP]2[/SUP], Zhou F[SUP]2[/SUP], Chen Z[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] In 2009, a global epidemic of influenza A (H1N1) caused the death of tens of thousands of people. Vaccination is the most effective means of controlling a wide-range epidemic of influenza and of reducing the mortality rate. In this study, the long-term immunogenicity of A/California/7/2009 (H1N1) split vaccine was observed as long as 15 months (450 days) after the immunization in mouse model. Female BALB/c mice were immunized intra-peritoneally with different doses of aluminum-adjuvanted vaccine. Four hundred fifty days after the immunization, the mice were challenged with a lethal dose (10 ? LD[SUB]50[/SUB]) of homologous virus. The results showed that the supplemented aluminum adjuvant could not only effectively enhance the protective effect of the vaccine, but also reduce the immunizing dose of the vaccine. In addition, the aluminum adjuvant could enhance the IgG antibody level of mice immunized with H1N1 split vaccine. The IgG level was correlated to the survival rate of the mice. Aluminum-adjuvanted inactivated split-virion 2009 pandemic influenza A H1N1 vaccine has good immunogenicity, and could provide long-term protection against lethal influenza virus challenge in mice.
Copyright ? 2015, American Society for Microbiology. All Rights Reserved.
PMID: 25589552 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25589552
[h=1]The long-term immunogenicity of an inactivated split-virion 2009 pandemic influenza A H1N1 vaccine with or without aluminium-adjuvantin mice.[/h] Xu W[SUP]1[/SUP], Zheng M[SUP]2[/SUP], Zhou F[SUP]2[/SUP], Chen Z[SUP]3[/SUP].
[h=3]Author information[/h]
[h=3]Abstract[/h] In 2009, a global epidemic of influenza A (H1N1) caused the death of tens of thousands of people. Vaccination is the most effective means of controlling a wide-range epidemic of influenza and of reducing the mortality rate. In this study, the long-term immunogenicity of A/California/7/2009 (H1N1) split vaccine was observed as long as 15 months (450 days) after the immunization in mouse model. Female BALB/c mice were immunized intra-peritoneally with different doses of aluminum-adjuvanted vaccine. Four hundred fifty days after the immunization, the mice were challenged with a lethal dose (10 ? LD[SUB]50[/SUB]) of homologous virus. The results showed that the supplemented aluminum adjuvant could not only effectively enhance the protective effect of the vaccine, but also reduce the immunizing dose of the vaccine. In addition, the aluminum adjuvant could enhance the IgG antibody level of mice immunized with H1N1 split vaccine. The IgG level was correlated to the survival rate of the mice. Aluminum-adjuvanted inactivated split-virion 2009 pandemic influenza A H1N1 vaccine has good immunogenicity, and could provide long-term protection against lethal influenza virus challenge in mice.
Copyright ? 2015, American Society for Microbiology. All Rights Reserved.
PMID: 25589552 [PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/25589552